Navigation Links
Particle Sciences Expands Biopharmaceutical Development Infrastructure
Date:7/15/2014

BETHLEHEM, Pa., July 15, 2014 /PRNewswire/ -- Particle Sciences, Inc. has expanded its development capabilities to accommodate the increasing demand for biopharmaceutical formulation and analysis.  According to Robert Becker, Vice President Biopharmaceutical Sales and Business Development at Particle Sciences, "Our company has been working with biologics for some time, accumulating significant infrastructure and intellectual property.  We regularly work with biopharmaceuticals and vaccines ranging from therapeutic proteins, including monoclonal antibodies, to nucleotides, to vaccine antigens and immunomodulators.  Adding cell culture and extensive instrumentation to support the testing and characterizations of these biopharmaceuticals was planned for later this year but we've accelerated implementation to meet our client's needs."   With this most recent expansion, Particle Sciences can now run the full gambit of testing including, among others, ELISA, SDS-PAGE, Western blots, image analysis, HPLC, HPLC-MS, ligand-receptor binding assays, cellular proliferation, cytotoxicity and cellular activation assays.   

Mark Mitchnick, Particle Sciences' CEO added, "This expansion augments our existing formulation and sterile manufacturing offerings.  With our unique approach to biopharmaceutical formulation and the ability to quickly take our clients into the clinic, Particle Sciences anticipates becoming a leader in large molecule formulation and clinical trial supply."  The company sees a rapidly growing industrial need for these services as biopharmaceutical and biosimilar products become an increasingly important component to the health care products market. Particle Sciences' formulation portfolio enables the broader, more efficient development and application of biopharmaceuticals, and can differentiate products in the biosimilars field.

Particle Sciences is an integrated provider of drug development services.  Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  We also have an extensive history in government contracting alongside our clients.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com,  email info@particlesciences.com or contact us at (610) 861- 4701 for information.

Contact: Maureen Grieco
Maureen.grieco@particlesciences.com


'/>"/>
SOURCE Particle Sciences
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Shimadzu Introduces New Particle Size Analyzer for Measurement of Nanoparticles in Life Sciences and R&D
2. New magnetic behavior in nanoparticles could lead to even smaller digital memories
3. DNA motor walks along nanotube, transports tiny particle
4. Nanoparticles and their orbital positions
5. Researchers split water into hydrogen, oxygen using light, nanoparticles
6. IceCube Particle Detector in Antarctica Records High-energy Neutrinos
7. Scientists develop way to successfully give nanoparticle therapeutics orally
8. Pills of the future: Nanoparticles
9. Ultra-sensitive force sensing with a levitating nanoparticle
10. Magnetic nanoparticles could aid heat dissipation
11. BHR Pharma Engages Particle Sciences to Develop Nasal Progesterone for Traumatic Brain Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
Breaking Biology News(10 mins):